GLI1 and medulloblastoma: Although it is unclear whether the promising clinical response to 4SC‐202 treatment was due to inhibition of GLI activity, the results of the present study warrant further clinical evaluation of 4SC‐202 as a treatment for GLI‐dependent cancers including BCC, medulloblastoma and possibly other malignancies with high medical need.